25 XP   0   0   10

Immunic Inc
Buy, Hold or Sell?

Let's analyse Immunic Inc together

PenkeI guess you are interested in Immunic Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Immunic Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Immunic Inc

I send you an email if I find something interesting about Immunic Inc.

Quick analysis of Immunic Inc (30 sec.)










What can you expect buying and holding a share of Immunic Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
2.5%

What is your share worth?

Current worth
$0.32
Expected worth in 1 year
$-0.62
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$-0.94
Return On Investment
-68.7%

For what price can you sell your share?

Current Price per Share
$1.37
Expected price per share
$1.17 - $1.73
How sure are you?
50%

1. Valuation of Immunic Inc (5 min.)




Live pricePrice per Share (EOD)

$1.37

Intrinsic Value Per Share

$-6.70 - $-5.01

Total Value Per Share

$-6.38 - $-4.69

2. Growth of Immunic Inc (5 min.)




Is Immunic Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$28.9m$122m-$62.6m-105.3%

How much money is Immunic Inc making?

Current yearPrevious yearGrowGrow %
Making money-$22.9m-$38.5m$15.6m68.4%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Immunic Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#524 / 1007

Most Revenue
#964 / 1007

Most Profit
#743 / 1007

Most Efficient
#394 / 1007

What can you expect buying and holding a share of Immunic Inc? (5 min.)

Welcome investor! Immunic Inc's management wants to use your money to grow the business. In return you get a share of Immunic Inc.

What can you expect buying and holding a share of Immunic Inc?

First you should know what it really means to hold a share of Immunic Inc. And how you can make/lose money.

Speculation

The Price per Share of Immunic Inc is $1.37. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Immunic Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Immunic Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.32. Based on the TTM, the Book Value Change Per Share is $-0.24 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.04 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Immunic Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.24-17.5%-0.26-19.0%-0.33-24.4%-0.21-15.6%-0.17-12.7%
Usd Book Value Change Per Share-0.22-15.8%-0.24-17.2%-0.04-2.7%0.010.7%0.00-0.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.1%
Usd Total Gains Per Share-0.22-15.8%-0.24-17.2%-0.04-2.7%0.010.7%0.00-0.2%
Usd Price Per Share1.50-1.74-4.83-7.82-8.71-
Price to Earnings Ratio-1.57--1.68--4.93--15.41--15.98-
Price-to-Total Gains Ratio-6.94--7.39-18.47--47.23--50.05-
Price to Book Ratio4.67-3.04-3.39-7.39-9.92-
Price-to-Total Gains Ratio-6.94--7.39-18.47--47.23--50.05-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.37
Number of shares729
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.240.01
Usd Total Gains Per Share-0.240.01
Gains per Quarter (729 shares)-171.476.68
Gains per Year (729 shares)-685.9026.71
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-686-69602717
20-1372-138205344
30-2058-206808071
40-2744-2754010798
50-3429-34400134125
60-4115-41260160152
70-4801-48120187179
80-5487-54980214206
90-6173-61840240233
100-6859-68700267260

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.045.00.00.0%
Book Value Change Per Share0.04.00.00.0%3.09.00.025.0%6.014.00.030.0%10.030.00.025.0%11.033.01.024.4%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%1.00.039.02.5%1.00.044.02.2%
Total Gains per Share0.04.00.00.0%3.09.00.025.0%6.014.00.030.0%10.030.00.025.0%11.033.01.024.4%

Fundamentals of Immunic Inc

About Immunic Inc

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Fundamental data was last updated by Penke on 2024-05-02 21:25:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Immunic Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Immunic Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Immunic Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Immunic Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.2%+207.2%
TTM--214.6%+214.6%
YOY--281.4%+281.4%
5Y--428.1%+428.1%
10Y--595.4%+595.4%
1.1.2. Return on Assets

Shows how efficient Immunic Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Immunic Inc to the Biotechnology industry mean.
  • -39.7% Return on Assets means that Immunic Inc generated $-0.40 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Immunic Inc:

  • The MRQ is -39.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -30.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-39.7%TTM-30.5%-9.2%
TTM-30.5%YOY-29.5%-1.0%
TTM-30.5%5Y-24.0%-6.5%
5Y-24.0%10Y-21.8%-2.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-39.7%-12.9%-26.8%
TTM-30.5%-12.3%-18.2%
YOY-29.5%-11.2%-18.3%
5Y-24.0%-13.5%-10.5%
10Y-21.8%-15.1%-6.7%
1.1.3. Return on Equity

Shows how efficient Immunic Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Immunic Inc to the Biotechnology industry mean.
  • -74.6% Return on Equity means Immunic Inc generated $-0.75 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Immunic Inc:

  • The MRQ is -74.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -45.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-74.6%TTM-45.4%-29.1%
TTM-45.4%YOY-32.8%-12.6%
TTM-45.4%5Y-29.1%-16.3%
5Y-29.1%10Y-25.7%-3.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-74.6%-16.5%-58.1%
TTM-45.4%-15.7%-29.7%
YOY-32.8%-14.1%-18.7%
5Y-29.1%-18.8%-10.3%
10Y-25.7%-19.7%-6.0%

1.2. Operating Efficiency of Immunic Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Immunic Inc is operating .

  • Measures how much profit Immunic Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Immunic Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Immunic Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--287.3%+287.3%
TTM--226.2%+226.2%
YOY--287.8%+287.8%
5Y--459.1%+459.1%
10Y--598.1%+598.1%
1.2.2. Operating Ratio

Measures how efficient Immunic Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Immunic Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.246-3.246
TTM-3.303-3.303
YOY-3.753-3.753
5Y-5.557-5.557
10Y-7.396-7.396

1.3. Liquidity of Immunic Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Immunic Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.12 means the company has $2.12 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Immunic Inc:

  • The MRQ is 2.124. The company is able to pay all its short-term debts. +1
  • The TTM is 4.269. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.124TTM4.269-2.145
TTM4.269YOY9.334-5.065
TTM4.2695Y8.117-3.848
5Y8.11710Y8.811-0.694
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.1243.821-1.697
TTM4.2694.161+0.108
YOY9.3345.313+4.021
5Y8.1176.113+2.004
10Y8.8116.474+2.337
1.3.2. Quick Ratio

Measures if Immunic Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Immunic Inc to the Biotechnology industry mean.
  • A Quick Ratio of 1.92 means the company can pay off $1.92 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Immunic Inc:

  • The MRQ is 1.916. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.071. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.916TTM4.071-2.155
TTM4.071YOY8.467-4.397
TTM4.0715Y7.551-3.481
5Y7.55110Y8.382-0.831
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9163.474-1.558
TTM4.0713.993+0.078
YOY8.4675.388+3.079
5Y7.5516.105+1.446
10Y8.3826.442+1.940

1.4. Solvency of Immunic Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Immunic Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Immunic Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.47 means that Immunic Inc assets are financed with 46.7% credit (debt) and the remaining percentage (100% - 46.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Immunic Inc:

  • The MRQ is 0.467. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.281. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.467TTM0.281+0.186
TTM0.281YOY0.092+0.189
TTM0.2815Y0.130+0.152
5Y0.13010Y0.175-0.045
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4670.347+0.120
TTM0.2810.340-0.059
YOY0.0920.272-0.180
5Y0.1300.368-0.238
10Y0.1750.388-0.213
1.4.2. Debt to Equity Ratio

Measures if Immunic Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Immunic Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 87.7% means that company has $0.88 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Immunic Inc:

  • The MRQ is 0.877. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.434. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.877TTM0.434+0.443
TTM0.434YOY0.102+0.332
TTM0.4345Y0.169+0.265
5Y0.16910Y0.154+0.014
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8770.395+0.482
TTM0.4340.411+0.023
YOY0.1020.339-0.237
5Y0.1690.438-0.269
10Y0.1540.469-0.315

2. Market Valuation of Immunic Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Immunic Inc generates.

  • Above 15 is considered overpriced but always compare Immunic Inc to the Biotechnology industry mean.
  • A PE ratio of -1.57 means the investor is paying $-1.57 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Immunic Inc:

  • The EOD is -1.430. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.566. Based on the earnings, the company is expensive. -2
  • The TTM is -1.676. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.430MRQ-1.566+0.136
MRQ-1.566TTM-1.676+0.110
TTM-1.676YOY-4.927+3.251
TTM-1.6765Y-15.412+13.737
5Y-15.41210Y-15.979+0.566
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.430-2.437+1.007
MRQ-1.566-2.599+1.033
TTM-1.676-2.764+1.088
YOY-4.927-4.018-0.909
5Y-15.412-6.401-9.011
10Y-15.979-6.590-9.389
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Immunic Inc:

  • The EOD is -2.174. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.380. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.206. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.174MRQ-2.380+0.206
MRQ-2.380TTM-2.206-0.174
TTM-2.206YOY-6.135+3.929
TTM-2.2065Y-14.317+12.111
5Y-14.31710Y-16.823+2.506
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.174-3.111+0.937
MRQ-2.380-3.321+0.941
TTM-2.206-3.598+1.392
YOY-6.135-5.480-0.655
5Y-14.317-8.353-5.964
10Y-16.823-8.955-7.868
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Immunic Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.67 means the investor is paying $4.67 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Immunic Inc:

  • The EOD is 4.266. Based on the equity, the company is fair priced.
  • The MRQ is 4.670. Based on the equity, the company is fair priced.
  • The TTM is 3.035. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD4.266MRQ4.670-0.405
MRQ4.670TTM3.035+1.635
TTM3.035YOY3.387-0.352
TTM3.0355Y7.393-4.358
5Y7.39310Y9.919-2.526
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.2662.051+2.215
MRQ4.6702.143+2.527
TTM3.0352.120+0.915
YOY3.3872.878+0.509
5Y7.3933.601+3.792
10Y9.9193.972+5.947
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Immunic Inc.

3.1. Institutions holding Immunic Inc

Institutions are holding 58.355% of the shares of Immunic Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31RTW INVESTMENTS, LLC4.82080.1016433525500
2023-12-31Gratus Capital LLC2.15890.1641194145425499915.1204
2023-09-30Omega Fund Management LLC1.98842.4143178816000
2023-12-31Vanguard Group Inc1.88040.00011691000284111.7088
2023-09-30Bvf Inc1.27810.0456114942500
2023-12-31UBS O'Connor LLC0.66750.0648600234-161453-21.1968
2023-12-31Acadian Asset Management LLC0.62190.0033559305-197945-26.14
2023-12-31Logos Global Management LP0.46840.05942118400
2023-12-31Geode Capital Management, LLC0.46440.0001417613209695.2866
2023-12-31BlackRock Inc0.4027036212653171.4902
2023-12-31Susquehanna International Group, LLP0.37250.000133495310234243.9971
2023-12-31Sierra Summit Advisors LLC0.36120.14213248293248290
2023-12-31COWEN AND COMPANY, LLC0.35260.031231705900
2023-12-31Soleus Capital Management, L.P.0.33360.049930000000
2023-09-30INNOVIS ASSET MANAGEMENT LLC0.3030.15432724578621746.2935
2023-09-30Schonfeld Strategic Advisors LLC0.26540.00272387006380036.478
2023-12-31Northern Trust Corp0.182901644395422549.1997
2023-12-31Two Sigma Advisers, LLC0.16390.0005147418-170300-53.601
2023-12-31State Street Corporation0.1399012580300
2023-12-31Two Sigma Investments LLC0.12950.0004116494-235973-66.949
Total 17.3563.234115607908+175438+1.1%

3.2. Funds holding Immunic Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-31Vanguard Institutional Extnd Mkt Idx Tr2.10390.002418952071375327264.547
2024-03-31Vanguard Total Stock Mkt Idx Inv1.44210.00011299004222041.739
2024-02-29Fidelity Extended Market Index0.25950.0009233800-1133-0.4823
2024-03-31BlackRock Extended Equity Market K0.25860.0021232915131364129.3577
2024-03-31A4Investments SICAV SIF ACCI IlanaA2EURH0.24983.07542250002500012.5
2024-03-28iShares Micro-Cap ETF0.21230.027519125500
2023-09-30BlackRock Extended Mkt Composite0.12920.001211640200
2023-12-31Bridgeway Ultra-Small Company Market0.12210.0888110000-35000-24.1379
2024-03-31Vanguard Balanced Index Inv0.10880.000298039980390
2024-03-31NT Ext Equity Mkt Idx Fd - L0.08960.00178074743728118.1231
2024-02-29Fidelity Total Market Index0.08010.00017219300
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.07880.00177098346296187.5319
2024-03-31Vanguard Instl Ttl Stk Mkt Idx InstlPls0.07760.000369930699300
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.06330.00175700937219188.0697
2024-02-29Fidelity Series Total Market Index0.05850.00015265700
2023-12-31Northern Trust Extended Eq Market Idx0.04110.00137019877231.0546
2024-03-31Vanguard U.S. Eq Idx £ Acc0.03540.00023186725147374.2113
2024-02-29Vifag 2002 SICAV0.03330.06873000000
2024-03-31Extended Equity Market Fund M0.03190.00212873116175128.8229
2024-03-31Schwab Total Stock Market Index0.02780.00012500000
Total 5.50373.27634957758+1863068+37.6%

3.3. Insider Transactions

Insiders are holding 7.724% of the shares of Immunic Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-05-15Glenn WhaleyBUY50001.75

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Immunic Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.216-0.235+9%-0.037-83%0.009-2460%-0.003-98%
Book Value Per Share--0.3210.660-51%1.355-76%1.057-70%0.845-62%
Current Ratio--2.1244.269-50%9.334-77%8.117-74%8.811-76%
Debt To Asset Ratio--0.4670.281+66%0.092+406%0.130+260%0.175+167%
Debt To Equity Ratio--0.8770.434+102%0.102+760%0.169+420%0.154+468%
Dividend Per Share----0%-0%-0%0.001-100%
Eps---0.239-0.260+8%-0.334+40%-0.214-11%-0.175-27%
Free Cash Flow Per Share---0.158-0.197+25%-0.181+15%-0.164+4%-0.142-10%
Free Cash Flow To Equity Per Share---0.151-0.195+29%0.240-163%0.084-279%0.037-508%
Gross Profit Margin--1.1751.044+13%1.000+17%1.009+16%1.004+17%
Intrinsic Value_10Y_max---5.014--------
Intrinsic Value_10Y_min---6.699--------
Intrinsic Value_1Y_max---0.558--------
Intrinsic Value_1Y_min---0.794--------
Intrinsic Value_3Y_max---1.634--------
Intrinsic Value_3Y_min---2.294--------
Intrinsic Value_5Y_max---2.659--------
Intrinsic Value_5Y_min---3.681--------
Market Cap123408230.000-9%135118500.000156962657.500-14%435306767.500-69%704043952.150-81%784403428.050-83%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio4.266-9%4.6703.035+54%3.387+38%7.393-37%9.919-53%
Pe Ratio-1.430+9%-1.566-1.676+7%-4.927+215%-15.412+884%-15.979+920%
Price Per Share1.370-9%1.5001.743-14%4.833-69%7.816-81%8.708-83%
Price To Free Cash Flow Ratio-2.174+9%-2.380-2.206-7%-6.135+158%-14.317+502%-16.823+607%
Price To Total Gains Ratio-6.336+9%-6.938-7.391+7%18.466-138%-47.225+581%-50.048+621%
Quick Ratio--1.9164.071-53%8.467-77%7.551-75%8.382-77%
Return On Assets---0.397-0.305-23%-0.295-26%-0.240-40%-0.218-45%
Return On Equity---0.746-0.454-39%-0.328-56%-0.291-61%-0.257-66%
Total Gains Per Share---0.216-0.235+9%-0.037-83%0.009-2460%-0.002-99%
Usd Book Value--28931000.00059460000.000-51%122075750.000-76%95254700.000-70%76102150.000-62%
Usd Book Value Change Per Share---0.216-0.235+9%-0.037-83%0.009-2460%-0.003-98%
Usd Book Value Per Share--0.3210.660-51%1.355-76%1.057-70%0.845-62%
Usd Dividend Per Share----0%-0%-0%0.001-100%
Usd Eps---0.239-0.260+8%-0.334+40%-0.214-11%-0.175-27%
Usd Free Cash Flow---14192000.000-17790500.000+25%-16314000.000+15%-14729400.000+4%-12757200.000-10%
Usd Free Cash Flow Per Share---0.158-0.197+25%-0.181+15%-0.164+4%-0.142-10%
Usd Free Cash Flow To Equity Per Share---0.151-0.195+29%0.240-163%0.084-279%0.037-508%
Usd Market Cap123408230.000-9%135118500.000156962657.500-14%435306767.500-69%704043952.150-81%784403428.050-83%
Usd Price Per Share1.370-9%1.5001.743-14%4.833-69%7.816-81%8.708-83%
Usd Profit---21572000.000-22900250.000+6%-38574000.000+79%-21148600.000-2%-16429600.000-24%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.216-0.235+9%-0.037-83%0.009-2460%-0.002-99%
 EOD+3 -5MRQTTM+16 -14YOY+8 -225Y+7 -2310Y+4 -28

4.2. Fundamental Score

Let's check the fundamental score of Immunic Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.430
Price to Book Ratio (EOD)Between0-14.266
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.916
Current Ratio (MRQ)Greater than12.124
Debt to Asset Ratio (MRQ)Less than10.467
Debt to Equity Ratio (MRQ)Less than10.877
Return on Equity (MRQ)Greater than0.15-0.746
Return on Assets (MRQ)Greater than0.05-0.397
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Immunic Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.187
Ma 20Greater thanMa 501.287
Ma 50Greater thanMa 1001.327
Ma 100Greater thanMa 2001.309
OpenGreater thanClose1.350
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets54,299
Total Liabilities25,368
Total Stockholder Equity28,931
 As reported
Total Liabilities 25,368
Total Stockholder Equity+ 28,931
Total Assets = 54,299

Assets

Total Assets54,299
Total Current Assets52,534
Long-term Assets1,765
Total Current Assets
Cash And Cash Equivalents 46,674
Net Receivables 703
Other Current Assets 5,157
Total Current Assets  (as reported)52,534
Total Current Assets  (calculated)52,534
+/-0
Long-term Assets
Property Plant Equipment 1,765
Long-term Assets  (as reported)1,765
Long-term Assets  (calculated)1,765
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities24,729
Long-term Liabilities639
Total Stockholder Equity28,931
Total Current Liabilities
Short-term Debt 695
Accounts payable 5,099
Other Current Liabilities 18,935
Total Current Liabilities  (as reported)24,729
Total Current Liabilities  (calculated)24,729
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt639
Long-term Liabilities  (as reported)639
Long-term Liabilities  (calculated)639
+/- 0
Total Stockholder Equity
Common Stock4
Retained Earnings -410,892
Accumulated Other Comprehensive Income 3,759
Other Stockholders Equity 436,060
Total Stockholder Equity (as reported)28,931
Total Stockholder Equity (calculated)28,931
+/-0
Other
Capital Stock4
Cash and Short Term Investments 46,674
Common Stock Shares Outstanding 44,633
Liabilities and Stockholders Equity 54,299
Net Debt -45,340
Net Invested Capital 28,931
Net Working Capital 27,805
Property Plant and Equipment Gross 1,765
Short Long Term Debt Total 1,334



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-30
> Total Assets 
0
20,332
0
45,760
37,979
46,585
55,608
97,016
85,831
108,082
94,924
79,872
66,943
89,081
82,920
78,632
72,473
64,026
90,947
80,675
70,358
60,384
47,008
34,801
19,988
14,978
10,482
72,574
67,604
65,955
57,292
87,152
171,640
167,861
154,724
136,058
156,757
139,100
149,920
138,657
121,083
127,753
108,872
88,739
66,977
54,299
54,29966,97788,739108,872127,753121,083138,657149,920139,100156,757136,058154,724167,861171,64087,15257,29265,95567,60472,57410,48214,97819,98834,80147,00860,38470,35880,67590,94764,02672,47378,63282,92089,08166,94379,87294,924108,08285,83197,01655,60846,58537,97945,760020,3320
   > Total Current Assets 
0
19,148
0
43,794
35,378
43,855
52,264
93,489
82,583
104,816
90,618
75,446
62,609
85,088
79,239
75,436
69,464
61,463
88,302
78,063
67,960
58,121
44,835
32,645
19,061
14,232
9,988
39,493
34,519
32,230
23,599
53,023
137,541
133,745
120,280
101,687
122,495
104,988
115,879
104,761
86,649
125,864
106,582
86,551
65,234
52,534
52,53465,23486,551106,582125,86486,649104,761115,879104,988122,495101,687120,280133,745137,54153,02323,59932,23034,51939,4939,98814,23219,06132,64544,83558,12167,96078,06388,30261,46369,46475,43679,23985,08862,60975,44690,618104,81682,58393,48952,26443,85535,37843,794019,1480
       Cash And Cash Equivalents 
0
4,477
0
36,439
31,158
38,186
46,041
90,840
79,091
102,238
88,257
71,946
59,754
83,416
77,876
73,598
68,088
59,991
86,636
76,153
66,391
56,901
43,647
31,116
17,798
13,324
9,595
36,121
30,460
29,369
18,578
48,607
133,183
127,452
114,839
87,175
110,444
86,863
95,710
88,078
72,771
106,745
92,761
77,294
59,689
46,674
46,67459,68977,29492,761106,74572,77188,07895,71086,863110,44487,175114,839127,452133,18348,60718,57829,36930,46036,1219,59513,32417,79831,11643,64756,90166,39176,15386,63659,99168,08873,59877,87683,41659,75471,94688,257102,23879,09190,84046,04138,18631,15836,43904,4770
       Short-term Investments 
0
13,996
0
5,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,629
4,351
0
0
0
0004,3519,62900000000000000000000000000000000000005,000013,9960
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
347
0
0
0
0
0
920
0
758
641
1,083
1,108
1,643
1,998
6,406
2,904
2,150
3,215
3,272
3,391
2,657
3,666
4,056
1,794
703
7031,7944,0563,6662,6573,3913,2723,2152,1502,9046,4061,9981,6431,1081,083641758092000000347000000000000000000000
       Other Current Assets 
0
675
0
2,355
4,220
3,506
6,223
2,649
3,492
2,578
2,361
3,500
2,855
1,672
1,363
1,838
1,376
1,472
1,666
1,910
1,569
1,220
1,188
1,529
1,263
908
393
2,452
4,059
2,861
670
655
4,358
1,234
886
1,496
1,275
1,122
1,548
16,683
1,549
1,225
9,470
1,389
1,447
5,157
5,1571,4471,3899,4701,2251,54916,6831,5481,1221,2751,4968861,2344,3586556702,8614,0592,4523939081,2631,5291,1881,2201,5691,9101,6661,4721,3761,8381,3631,6722,8553,5002,3612,5783,4922,6496,2233,5064,2202,35506750
   > Long-term Assets 
0
1,184
0
1,966
2,601
2,730
3,344
3,527
3,248
3,266
4,306
4,426
4,334
3,993
3,681
3,196
3,009
2,563
2,645
2,612
2,398
2,263
2,173
2,156
927
746
494
33,081
33,085
33,725
33,693
34,129
34,099
34,116
34,444
34,371
34,262
34,112
34,041
33,896
34,434
1,889
2,290
2,188
1,743
1,765
1,7651,7432,1882,2901,88934,43433,89634,04134,11234,26234,37134,44434,11634,09934,12933,69333,72533,08533,0814947469272,1562,1732,2632,3982,6122,6452,5633,0093,1963,6813,9934,3344,4264,3063,2663,2483,5273,3442,7302,6011,96601,1840
       Property Plant Equipment 
0
1,184
0
1,768
2,403
2,467
3,081
3,264
2,985
3,068
4,108
4,212
4,163
3,809
3,428
3,014
2,922
2,505
2,489
2,430
2,272
2,155
2,072
2,059
890
709
482
111
115
713
681
1,117
1,087
1,104
1,432
1,359
1,250
1,100
1,029
884
1,422
1,846
2,247
2,145
1,700
1,765
1,7651,7002,1452,2471,8461,4228841,0291,1001,2501,3591,4321,1041,0871,1176817131151114827098902,0592,0722,1552,2722,4302,4892,5052,9223,0143,4283,8094,1634,2124,1083,0682,9853,2643,0812,4672,4031,76801,1840
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
32,970
32,970
32,970
32,970
32,970
32,970
32,970
32,970
32,970
32,970
32,970
32,970
32,970
32,970
0
0
0
0
0
0000032,97032,97032,97032,97032,97032,97032,97032,97032,97032,97032,97032,97032,97032,970000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,735
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
32,970
0
0
0
0
0
0000032,9700000000000000000002,735000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
37
12
0
0
42
42
42
42
943
42
42
42
42
42
42
42
43
0
43
0
0
004304342424242424242943424242420012370000000000000000000000000
> Total Liabilities 
0
27,964
0
69,927
70,862
5,167
113,624
7,853
8,781
10,519
11,146
10,136
8,265
6,756
4,872
4,485
4,713
5,580
6,519
7,338
8,280
10,340
9,713
8,348
5,736
2,551
1,433
3,163
7,077
7,592
6,804
8,467
8,765
9,076
17,278
15,316
11,292
11,985
11,959
10,809
12,273
14,069
17,654
19,455
18,570
25,368
25,36818,57019,45517,65414,06912,27310,80911,95911,98511,29215,31617,2789,0768,7658,4676,8047,5927,0773,1631,4332,5515,7368,3489,71310,3408,2807,3386,5195,5804,7134,4854,8726,7568,26510,13611,14610,5198,7817,853113,6245,16770,86269,927027,9640
   > Total Current Liabilities 
0
1,745
0
9,102
7,621
4,846
8,633
7,561
8,498
10,278
10,946
9,977
8,119
6,655
4,816
4,473
4,630
5,480
6,450
7,292
8,234
10,281
9,666
8,299
5,691
2,510
1,433
3,122
7,036
7,072
6,333
7,674
8,030
8,397
16,356
14,487
10,591
11,401
11,457
10,402
11,514
13,077
16,302
18,241
17,781
24,729
24,72917,78118,24116,30213,07711,51410,40211,45711,40110,59114,48716,3568,3978,0307,6746,3337,0727,0363,1221,4332,5105,6918,2999,66610,2818,2347,2926,4505,4804,6304,4734,8166,6558,1199,97710,94610,2788,4987,5618,6334,8467,6219,10201,7450
       Short-term Debt 
0
0
0
8
125
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
26
0
0
3,298
3,963
5,450
0
125
388
189
406
408
404
366
395
571
649
671
662
695
69566267164957139536640440840618938812505,4503,9633,29800260000000000000000000001258000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
26
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000002600000000000000000000000000
       Accounts payable 
0
1,144
0
2,557
1,720
1,224
1,325
1,461
696
10,278
1,128
9,977
8,119
6,655
885
887
1,193
5,480
1,308
1,076
981
1,049
893
1,075
1,131
268
184
1,462
3,718
2,423
1,432
1,728
3,419
3,700
1,276
3,861
2,867
3,745
2,885
4,117
3,748
4,037
5,241
4,348
2,846
5,099
5,0992,8464,3485,2414,0373,7484,1172,8853,7452,8673,8611,2763,7003,4191,7281,4322,4233,7181,4621842681,1311,0758931,0499811,0761,3085,4801,1938878856,6558,1199,9771,12810,2786961,4611,3251,2241,7202,55701,1440
       Other Current Liabilities 
0
601
0
4,685
2,467
3,622
7,308
6,100
7,802
9,125
9,818
9,057
7,570
5,434
3,931
3,586
3,437
4,700
5,142
6,216
7,253
9,232
8,773
7,224
4,560
2,242
1,249
1,660
3,318
343
275
361
4,611
4,697
93
311
173
585
8,168
5,919
7,371
8,469
10,412
257
261
18,935
18,93526125710,4128,4697,3715,9198,168585173311934,6974,6113612753433,3181,6601,2492,2424,5607,2248,7739,2327,2536,2165,1424,7003,4373,5863,9315,4347,5709,0579,8189,1257,8026,1007,3083,6222,4674,68506010
   > Long-term Liabilities 
0
26,219
0
60,825
63,241
321
104,991
292
283
241
200
159
146
101
56
12
83
100
69
46
46
59
47
49
45
41
41
41
41
520
471
793
735
679
922
829
701
584
502
407
759
992
1,352
1,214
789
639
6397891,2141,3529927594075025847018299226797357934715204141414145494759464669100831256101146159200241283292104,99132163,24160,825026,2190
       Warrants
0
0
0
0
0
0
104,712
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000104,712000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
48
41
41
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000041414800000000000000000000000000
> Total Stockholder Equity
0
-7,632
0
-24,167
-32,883
41,418
-58,016
89,163
77,050
97,563
83,778
69,736
58,678
82,325
78,048
74,147
67,760
58,446
84,428
73,337
62,078
50,044
37,295
26,453
14,252
12,427
9,049
69,411
60,527
58,363
50,488
78,685
162,875
158,785
137,446
120,742
145,465
127,115
137,961
127,848
108,810
113,684
91,218
69,284
48,407
28,931
28,93148,40769,28491,218113,684108,810127,848137,961127,115145,465120,742137,446158,785162,87578,68550,48858,36360,52769,4119,04912,42714,25226,45337,29550,04462,07873,33784,42858,44667,76074,14778,04882,32558,67869,73683,77897,56377,05089,163-58,01641,418-32,883-24,1670-7,6320
   Common Stock
0
0
0
0
0
1
-1,363
2
2
2
2
2
2
3
3
3
3
3
4
4
4
4
4
4
4
4
4
1
1
1
1
1
2
2
2
2
3
3
3
3
3
4
4
4
4
4
444443333322221111144444444433333222222-1,363100000
   Retained Earnings Total Equity00-366,551-342,552-317,2800-239,582-217,681-196,873-175,688-156,396-138,462-103,928-92,7690-68,398-59,911-52,220-44,005-346,909-337,428-334,964-323,023-310,341-295,953-281,365-268,884-256,477-243,800-232,091-221,913-212,444-202,856-192,996-180,697-165,590-150,833-136,878-124,080-113,914000000
   Accumulated Other Comprehensive Income 
0
88
0
94
95
96
95
95
95
89
90
88
81
80
80
80
80
83
84
90
88
78
75
80
80
80
80
-722
-1,804
-1,373
-1,682
-1,608
-1,752
-4,112
-1,121
-1,398
-800
-252
-310
-660
-386
3,035
3,811
3,982
3,905
3,759
3,7593,9053,9823,8113,035-386-660-310-252-800-1,398-1,121-4,112-1,752-1,608-1,682-1,373-1,804-7228080808075788890848380808080818890899595959695940880
   Capital Surplus 
0
0
0
0
0
0
55,803
213,146
213,831
248,305
249,276
250,343
251,591
285,098
290,409
295,977
299,768
302,185
340,817
342,127
343,351
345,915
347,557
349,392
349,132
349,771
355,874
114,137
114,550
119,646
120,567
0
257,394
266,823
277,027
278,534
321,950
324,237
355,949
368,087
0
427,925
429,955
431,849
0
0
00431,849429,955427,9250368,087355,949324,237321,950278,534277,027266,823257,3940120,567119,646114,550114,137355,874349,771349,132349,392347,557345,915343,351342,127340,817302,185299,768295,977290,409285,098251,591250,343249,276248,305213,831213,14655,803000000
   Treasury Stock0000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
62,728
0
61,689
59,949
144,487
55,803
116,130
128,000
248,305
249,276
250,343
251,591
285,098
290,409
295,977
299,768
302,185
340,817
342,127
343,351
345,915
347,557
349,392
349,132
349,771
355,874
41,563
46,946
119,646
120,567
160,148
257,394
266,823
277,027
278,534
321,950
324,237
355,949
368,087
369,999
427,925
429,955
431,849
433,818
436,060
436,060433,818431,849429,955427,925369,999368,087355,949324,237321,950278,534277,027266,823257,394160,148120,567119,64646,94641,563355,874349,771349,132349,392347,557345,915343,351342,127340,817302,185299,768295,977290,409285,098251,591250,343249,276248,305128,000116,13055,803144,48759,94961,689062,7280



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-111
Gross Profit-111-111
 
Operating Income (+$)
Gross Profit-111
Operating Expense-99,112
Operating Income-99,223-99,223
 
Operating Expense (+$)
Research Development83,215
Selling General Administrative16,008
Selling And Marketing Expenses111
Operating Expense99,11299,334
 
Net Interest Income (+$)
Interest Income3,075
Interest Expense-0
Other Finance Cost-0
Net Interest Income3,075
 
Pretax Income (+$)
Operating Income-99,223
Net Interest Income3,075
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-93,612-104,834
EBIT - interestExpense = -99,223
-93,612
-93,612
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-99,223-93,612
Earnings Before Interest and Taxes (EBITDA)-99,112
 
After tax Income (+$)
Income Before Tax-93,612
Tax Provision-0
Net Income From Continuing Ops-93,612-93,612
Net Income-93,612
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses99,223
Total Other Income/Expenses Net5,611-3,075
 

Technical Analysis of Immunic Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Immunic Inc. The general trend of Immunic Inc is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Immunic Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Immunic Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.46 < 1.64 < 1.73.

The bearish price targets are: 1.17 > 1.17 > 1.17.

Tweet this
Immunic Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Immunic Inc. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Immunic Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Immunic Inc. The current macd is -0.0019704.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Immunic Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Immunic Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Immunic Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Immunic Inc Daily Moving Average Convergence/Divergence (MACD) ChartImmunic Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Immunic Inc. The current adx is 9.24525321.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Immunic Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Immunic Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Immunic Inc. The current sar is 1.18572416.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Immunic Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Immunic Inc. The current rsi is 58.19. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Immunic Inc Daily Relative Strength Index (RSI) ChartImmunic Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Immunic Inc. The current phase is Overbought in neutral market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Immunic Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Immunic Inc Daily Stochastic Oscillator ChartImmunic Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Immunic Inc. The current cci is 107.04.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Immunic Inc Daily Commodity Channel Index (CCI) ChartImmunic Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Immunic Inc. The current cmo is 29.22.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Immunic Inc Daily Chande Momentum Oscillator (CMO) ChartImmunic Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Immunic Inc. The current willr is -9.09090909.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Immunic Inc Daily Williams %R ChartImmunic Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Immunic Inc.

Immunic Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Immunic Inc. The current atr is 0.08595168.

Immunic Inc Daily Average True Range (ATR) ChartImmunic Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Immunic Inc. The current obv is 70,589,976.

Immunic Inc Daily On-Balance Volume (OBV) ChartImmunic Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Immunic Inc. The current mfi is 44.58.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Immunic Inc Daily Money Flow Index (MFI) ChartImmunic Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Immunic Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-14BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-19MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-09WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-29MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-11CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-12BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-26STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-05-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside

6.3. Candlestick Patterns

Immunic Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Immunic Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.187
Ma 20Greater thanMa 501.287
Ma 50Greater thanMa 1001.327
Ma 100Greater thanMa 2001.309
OpenGreater thanClose1.350
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Immunic Inc with someone you think should read this too:
  • Are you bullish or bearish on Immunic Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Immunic Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Immunic Inc

I send you an email if I find something interesting about Immunic Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Immunic Inc.

Receive notifications about Immunic Inc in your mailbox!